ONCY significantly ahead of the oncolytic viral therapy research curve - German researchers enters space
Scientists at the prestigious German Paul Ehrlich Institute (PEI) have begun research on oncolytic viruses to treat cancer with the below referenced success in mice. Once again ONCY is way ahead of the curve in the development of oncolytic viruses (reovirus) as a novel therapeutic in the treatment of cancer.
Search: Scientists Generate Oncolytic Viruses for Targeted Attack on Cancer Stem Cells
Source: German Cancer Research Centre (DKFZ)
"Researchers from the Paul Ehrlich Institute (PEI) have been the first to generate oncolytic viruses which specifically infect and kill CD133-positive cancer stem cells. Using such viruses, scientists at the German Cancer Research Center (DKFZ) and the National Center for Tumor Diseases (NCT) Heidelberg were able to substantially reduce tumor growth in cell cultures and in an animal model. Cancer Research reports on these research results in its online edition of January 4, 2013.
Tumors are usually not made up of a homogenous cell population whose cells all respond with the same sensitivity to different types of therapy. Instead, many tumor types are suspected to contain cancer stem cells, which usually respond poorly to chemotherapy and radiotherapy and are considered to be responsible for metastasis. Scientists are therefore trying to find ways of identifying and eliminating such cells, which are also known as tumor-initiating cells.
The cell surface protein CD133 is a candidate being discussed as a characteristic marker for such cancer stem cells. Researchers led by Professor Christian Buchholz at the Paul Ehrlich Institute in Langen modified a weakened and thus harmless measles virus, which is used as a vaccine, for targeted attack on cancer stem cells. The modified virus needs the CD133 surface protein as a receptor to penetrate the cell. The researchers were able to prove in mixed cell cultures that the modified virus infects only cells with this surface protein.
In collaboration with research groups led by Professor Hanno Glimm of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the National Center for Tumor Diseases (NCT) and by Professor Christel Herold-Mende at Heidelberg University, the scientists then tested the antitumor effect of their targeted virus using mouse models for glioma, colon cancer, and liver cancer. "The modified virus showed pronounced antitumor activity in all animal models tested. "
how the hell do you GENERATE a virus? Is it like you dip two magnetic metal plates in mixture of proteins and rub them together. Have the plates wire connected to electrodes spaced 1nm apart. The viruses just drop off like pennies from heaven. Generation and modification in scientific document are as alike as fire and water. Amateurs.Go ONCY.